Anestacon Jelly

Lidocaine hydrochloride jelly USP, 2% (Anestacon®) is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).

To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy, or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

There have been rare reports of endotracheal tube occlusion associated with the presence of dried jelly residue in the inner lumen of the tube. (See also WARNINGS and DOSAGE AND ADMINISTRATION.)

Lidocaine Hydrochloride Jelly USP, 2% (Anestacon®) is supplied in 15 mL unit-dose disposable container for SINGLE PATIENT USE.

Store at control room temperature 20° to 25°C (68° to 77°F) [see USP].

Manufactured by:
Hi-Tech Pharmacal Co., Inc.
Amityville, NY 11701

Rev. 772:00 6/13